[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nazarbayev University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":178},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,67,96,127,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100644996","health-body-composition-and-nutrition-research-among-women-in-kazakhstan-100644996",false,"NCT07675486","Health, Body Composition, and Nutrition Research Among Women in Kazakhstan","Understanding Women's Health in Kazakhstan: Body Composition as a Key Indicator for Precision Nutrition and Predictive Healthcare","HER-KZ","Inclusion Criteria:\n\n* Female sex\n* Age ≥20 years at the time of consent\n* Natural postmenopause (≥12 consecutive months of amenorrhoea not attributable to other pathological or pharmacological causes) OR surgical postmenopause (bilateral oophorectomy)\n* Resident of Astana or the surrounding region with no planned relocation during the study period\n* Able to provide written informed consent independently\n* Able to complete the questionnaire in Kazakh, Russian, or English\n\nExclusion Criteria:\n\n* Active malignancy or systemic anti-cancer treatment (chemotherapy, radiotherapy, immunotherapy) within the past 5 years\n* Conditions causing secondary changes in muscle mass or body composition: hyperthyroidism (untreated), Cushing's syndrome, acromegaly, severe liver disease (Child-Pugh B or C), advanced chronic kidney disease (Stage 4 or 5, eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²)\n* Neuromuscular disorders that independently affect skeletal muscle mass (e.g., myopathy, motor neurone disease, multiple sclerosis)\n* Long-term systemic corticosteroid therapy (\\>3 months in the past year, equivalent to ≥5 mg\u002Fday prednisolone)\n* Severe skeletal deformity (kyphoscoliosis, limb absence) or presence of metallic implants (hip or knee prosthesis on both sides, bilateral rods) that would significantly compromise DEXA body composition validity\n* Physical inability to stand or to complete the functional assessments safely\n* Cognitive impairment or psychiatric condition precluding independent informed consent, as determined by the recruiting research team member","FEMALE","20 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the association between dietary intake, physical activity, sleep quality, and body composition in women in Kazakhstan. The study will recruit approximately 200 women aged 20 years and older undergoing routine DEXA examinations in Astana. Participants will complete validated questionnaires assessing diet, physical activity, sleep quality, and sarcopenia risk, alongside functional assessments. DEXA scans will provide measurements of fat mass, lean mass, visceral adipose tissue, bone mineral density, and appendicular skeletal muscle mass. The primary objective is to evaluate associations between dietary quality and DEXA-derived outcomes. Secondary objectives include assessing sarcopenia prevalence and examining relationships between physical activity, sleep quality, supplement use, and body composition. An optional second stage will explore associations between body composition and existing inflammatory and metabolic biomarkers from medical records. The findings are expected to provide the first comprehensive DEXA-based dataset on women's body composition and lifestyle factors in Kazakhstan and inform public health strategies.",[25,26,27,28],"Body Composition Changes","Dietary Intakes","Sleep","Physical Activity","NOT_YET_RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":21},"2026-07",{"date":37,"type":21},"2029-07",{"name":39,"class":40},"Nazarbayev University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100625213","grape-polyphenols-for-prevention-of-chemotherapy-induced-cardiotoxicity-100625213","NCT07419711","Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity","Cardioprotective Effects of Grape Polyphenols to Reduce Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients: A Randomized Pilot Study","Inclusion Criteria:\n\n* Female patients aged 30 to 75 years.\n* Histologically confirmed breast cancer.\n* Planned treatment with anthracycline- and\u002For trastuzumab-based chemotherapy.\n* High or very high risk of chemotherapy-induced cardiotoxicity (≥20%), based on clinical assessment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3.\n* Ability to take oral study products.\n* Willingness to comply with study procedures and follow-up visits.\n* Written informed consent provided prior to any study procedures.\n\nExclusion Criteria:\n\n* ECOG performance status of 4.\n* Pre-existing severe cardiovascular disease that would interfere with study participation.\n* Permanent atrial fibrillation or other clinically significant arrhythmias.\n* Severe hepatic or renal impairment.\n* Active central nervous system tumors or metastases.\n* Uncontrolled arterial hypertension.\n* Acute gastrointestinal diseases that may impair absorption.\n* Known allergy or intolerance to grape products or study components.\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.","30 Years","75 Years",{"count":51,"type":21},120,"INTERVENTIONAL",[54],"NA","This pilot randomized clinical study aims to evaluate the cardioprotective effects of a grape polyphenol concentrate in patients receiving anthracycline- and\u002For trastuzumab-based chemotherapy. Adult patients at high or very high risk of chemotherapy-induced cardiotoxicity will be randomized to receive either a grape polyphenol concentrate or placebo for three months, starting with chemotherapy. Cardiac function and cardiotoxicity will be assessed using echocardiographic parameters and circulating biomarkers at baseline, 3 months, and 6 months.",[57,58],"Chemotherapy-induced Cardiotoxicity","Breast Cancer","2026-02-16",{"date":61,"type":33},"2026-02-19",{"date":63,"type":21},"2026-02-09",{"date":65,"type":21},"2027-11-01",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":52,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100601540","cervical-cancer-screening-via-self-sampling-100601540","NCT07111819","Cervical Cancer Screening Via Self-sampling","Cervical Cancer Screening Using Self-sampling Approach: Validation of Human Papillomavirus Self-sampling Kits Among Kazakhstani Women","Inclusion Criteria:\n\nEligible participants will be recruited from different outpatient clinics in Kazakhstan located in the different regions (western, eastern, northern, southern, and central parts) of the country, and must meet the following inclusion criteria:\n\n1. age - women 18 years and older;\n2. Intact uterine cervix (no prior total hysterectomy or trachelectomy);\n3. ability to understand and answer questions\u002Fsurveys in Kazakh, Russian or English.\n\nExclusion Criteria:\n\npatients who are\n\n1. younger than 18 years old,\n2. women after total hysterectomy (or other surgery, when the uterine cervix is removed),\n3. pregnant women, and\n4. those who are not able to answer questions in Kazakh, Russian or English will be excluded.",true,"18 Years","70 Years",{"count":78,"type":21},1000,[54],"Prevention of cervical cancer is one of the priority areas of the Comprehensive Plan to Combat Cancer in the Republic of Kazakhstan for 2023-2027. High-risk human papillomavirus (HR-HPV) infections cause a wide variety of benign and malignant conditions, including cervical cancer. More than 90% of cervical cancer cases are attributed to HR-HPV infections, with HPV-16 and HPV-18 being reported to cause 70-75% of cases. At the present time, cervical cancer remains the fourth most prevalent cancer among women worldwide. Moreover, the majority of cervical cancer cases (90%) occur in low- and middle-income countries (LMICs), where cervical cancer remains the leading cause of death from cancer. Each year, the number of cervical cancer cases is dynamically increasing globally. Between 2000 and 2020 the absolute number of cervical cancer cases increased from 471 000 to 600 000. In 2020, there were around 350,000 deaths from cervical cancer. Moreover, by 2030 it is estimated that the number of new cervical cancer cases will reach 700 000, and the annual number of deaths will reach 400 000. Therefore, given such a significant annual increase in the number of cases and deaths, the elimination of cervical cancer is a global public health challenge.\n\nThe prevalence of HPV infection in Kazakhstan is high, around 39% among women attending gynecological clinics. Consequently, the cervical cancer incidence in Kazakhstan has increased over the past decade, and cervical cancer is the second leading cancer type among women in the country. Moreover, among Central Asian countries, Kazakhstan has the second-highest incidence rate of cervical cancer. The cervical cancer screening program is covered by the government and utilizes Papanicolaou test (Pap-test) performed by gynecologists in outpatient clinics all over the country. However, the screening coverage was reported to be low, covering only around 46% of the eligible population, and does not reach the demand level of 70% suggested by the World Health Organization (WHO). Furthermore, the national HPV vaccination program has just started in September 2024 and could contribute to the reduction of cervical cancer incidence only in the coming 10 years when the effect of vaccination will have an impact on the decrease of HPV prevalence in the country. A proper cervical cancer screening and screening coverage play a crucial role in cervical cancer prevention and control. Thus, there are many factors found to have an impact on overall screening behavior among Kazakhstani women and the increasing incidence of cervical cancer in the country. However, the current screening practices do not show high efficacy due to low coverage and general low sensitivity of the method used. These factors result in growing cervical cancer incidence in Kazakhstan. Thus, there is an emergent need to improve the screening process by introducing novel and reliable methods of screening. Cervical self-sampling could potentially improve the screening coverage; however, the approach should be validated to prove its effectiveness in the Kazakhstani cultural setting before introduction to the healthcare system.",[82],"Cervical Cancer Screening",[84,85,86,87],"Cervical cancer prevention","HPV","Cervical cancer screening","HPV self-sampling","2025-08-05",{"date":90,"type":33},"2025-08-08",{"date":92,"type":21},"2025-08-01",{"date":94,"type":21},"2027-12-31",{"name":39,"class":40},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":52,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100571509","effectiveness-of-reboa-in-reducing-blood-loss-during-cesarean-section-in-patients-with-pas-100571509","NCT06721182","Effectiveness of REBOA in Reducing Blood Loss During Cesarean Section in Patients with PAS","Effectiveness of Endovascular Balloon Occlusion of the Aorta in Reducing Blood Loss During Cesarean Section in Patients with Placenta Accreta Spectrum Disorders in Tertiary Care Center in Kazakhstan: a Randomized Controlled Trial","Inclusion Criteria: (1) singleton pregnancy at 34 weeks of gestation or more, (2) age 18 to 45 years, (3) confirmed diagnosis of placenta accreta spectrum, (4) indication for elective cesarean section, (5) consent for aortic balloon occlusion during cesarean section -\n\nExclusion Criteria:(1) pregnant patients at the gestational age ˂ 34 weeks of gelation, (2) multiple pregnancy, (3) need for emergency caesarean section, (4) coagulopathy (known coagulopathy, women with abnormal baseline activated partial thromboplastin time (aPTT), prothrombin time (PT), international normalization ratio (INR) before surgery)\n\n\\-","45 Years",{"count":105,"type":21},100,[54],"Obstetric hemorrhage is one of the leading causes of maternal mortality and morbidity worldwide. The major risk factors for obstetric hemorrhage include placenta previa and placenta accreta spectrum (PAS) disorders. The frequency of PAS disorders is increasing worldwide and is accompanied by intraoperative massive bleeding with hemorrhagic shock and increasing rates of cesarean hysterectomy. To decrease risks of bleeding, various approached of endovascular balloon occlusion are tested during the recent decade. This study aims to evaluate the effectiveness of resuscitative endovascular balloon occlusion of the aorta (REBOA) in reducing blood loss and preserving the reproductive organs during cesarean section. This will be a prospective randomized controlled trial involving 100 patients in tertiary care obstetric center in Kazakhstan. The study population will consist of pregnant women who will be admitted to the University Medical Center for cesarean section due to placenta previa complicated by PAS disorders. Study subjects will be randomly divided in intervention and control groups. The results will be analyzed through the measurement of primary (blood loss during cesarean section) and secondary outcomes \\[occurrence of hysterectomy during cesarean section, blood transfusion volume, duration of surgery, balloon application time, stay in intensive care unit (ICU), neonatal outcomes, complications, and total days of postsurgical hospital stay\\]. Use of REBOA is expected to minimize intraoperative blood loss during cesarean section, decrease the need for transfusion of blood components, reduce the time of surgical intervention, and decrease the rate of maternal complications and reduce the rate of cesarean hysterectomy.",[109],"Placenta Accreta Spectrum",[111,112,113,114,115,116,117,118],"REBOA","obstetric hemorrhage","cesarean hysterectomy","placenta accreta spectrum","clinical outcome","cesarean section","endovascular balloon occlusion","abnormally invasive placenta","2024-12-03",{"date":121,"type":33},"2024-12-06",{"date":123,"type":21},"2024-12-20",{"date":125,"type":21},"2026-12-01",{"name":39,"class":40},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":134,"minAge":75,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},"100563958","ventriculo-arterial-coupling-and-intra-dialytic-changes-in-hemodialysis-patients-prognostic-insights-100563958","NCT06622928","Ventriculo-Arterial Coupling and Intra-Dialytic Changes in Hemodialysis Patients: Prognostic Insights","Ventriculo-arterial Coupling in Patients With End-stage Renal Disease on Hemodyalisis: Intra-dialytic Changes and Prognostic Value.","Inclusion Criteria:\n\n* 18 years or older;\n* Standard renal replacement schedule with 3 dialysis sessions per week;\n* Dialysis vintage of at least 3 months;\n* Dialysis adequacy with single-pool Kt\u002FV \\>1.2\n\nExclusion Criteria:\n\n* Previous kidney transplantation\n* Myocardial infarction, unstable angina or stroke during the previous 6 months;\n* Severe stage III to IV congestive heart failure according to the NYHA classification;\n* Chronic atrial fibrillation or other known arrhythmia;\n* History of non-adherence to the prescribed weekly dialysis schedule in the previous month;\n* Body mass index \\>40 Kg\u002Fm2; or\n* History of malignancy or other clinical conditions associated with very poor prognosis.","ALL",{"count":136,"type":21},384,"The acute effect of hemodialysis (HD) on left ventricular mechanics has been evaluated in several studies, however their results are not uniform. Eventually, the heart and the arterial system behave as an interconnected system and not as isolated structures; thus, the evaluation of the interaction of cardiac contractility with the arterial system would provide a more comprehensive understanding of the cardiovascular function and cardiac energetics. However, there have not been any studies demonstrating changes in terms of volumes, contractility, intraventricular pressure gradients distribution, and vascular properties in response to changes in loading conditions and their impact on the outcome.\n\nWith these concepts in mind, we aim to evaluate the effect of volume changes induced by HD on ventriculo-arterial coupling (VAC) computed from speckle-tracking echocardiography. In particular, we seek to study patients with end-stage renal disease (ESRD) to assess:\n\n1. VAC parameters before and after the hemodialysis session;\n2. The value of VAC parameters in predicting adverse outcome\n\nThree-hundred-eighty-four patients with ESRD will be evaluated by standard 2-D echocardiography before and after the HD session. Echocardiographic speckle tracking images will be analysed off-line using a dedicated software based on a mathematical model (QStrain, Medis BV, Leiden, NL). The software reconstructs the pressure\u002Fvolume (PV) loop by determining the end-systolic and end-diastolic pressure-volume relationship using the single-beat algorithms. The PV relation will be depicted for the entire cardiac cycle where each point of the curve is described as (Vt, Pt). Based on this integrated PV loop analysis, the following hemodynamic parameters will be calculated: LV systolic elastance (Ees); Arterial elastance (Ea); Ventricular-Arterial Coupling (VAC); Stroke Work (SW); Pressure-volume area (PVA); Work efficiency (WE).\n\nPatients will be followed-up for 18 months. Primary end-point will be a composite of all-cause of death, nonfatal myocardial infarction, and hospitalization due to worsening heart failure. Secondary end-point will be a composite of cardiac death, nonfatal myocardial infarction, and hospitalization for heart failure. Event-free survival for each of the echocardiographic and VAC parameters will be assessed using Kaplan-Meier analysis and compared with a log-rank test, where each index will be dichotomized according to the median of its distribution. The prognostic value will be determined using the Cox proportional hazards model. Differences will be considered statistically significant when p \\<0.05.",[139,140],"Hemodialysis","Ventriculo-arterial Coupling",[142,143,144,145,146],"hemodialysis","end-stage renal disease","ventriculo-arterial coupling","advanced echocardiography","cardiac ultrasound","2024-09-29",{"date":149,"type":33},"2024-10-02",{"date":151,"type":21},"2024-10-01",{"date":153,"type":21},"2026-11-01",{"name":39,"class":40},1,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":134,"minAge":75,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":52,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":155},"100560188","the-gut-microbiome-in-chronic-heart-failure-100560188","NCT06573892","The Gut Microbiome in Chronic Heart Failure","Development of a Panel of Microbiome Markers for Predicting CHF Outcomes","GMCHF","Inclusion Criteria:\n\n* Age over 18 years\n* Residing in the city of Astana and surrounding regions (Akmola region)\n* Diagnosis of heart failure according to internationally recognized guidelines and classified as Class I-IV by NYHA (New York Heart Association) or Stage A-C according to ACC\u002FAHA (American College of Cardiology\u002FAmerican Heart Association) classification\n* Clinically stable condition and optimized medication therapy for heart failure for at least 4 weeks in accordance with current recommendations\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* • Age under 18 years\n\n  * Refusal to undergo diagnostic procedures specified in the study protocol\n  * Terminal stage of heart failure (Stage D according to ACC\u002FAHA classification)\n  * Coronary or peripheral revascularization procedures, valvular procedures, or any major surgical procedure within 3 months prior to study enrollment\n  * Use of antibiotics, cytostatic therapy, or pro- or prebiotics within 1 month prior to the baseline visit\n  * Presence of oncological and autoimmune diseases (connective tissue diseases, gastrointestinal disorders, skin disorders, etc.)\n  * Acute illness or active infection\n  * Individual intolerance to the administered nutrients (probiotics)\n  * Presence of other anatomical or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, may limit the subject's ability to participate in the clinical study, comply with the requirements of subsequent follow-up, or affect the scientific validity of the clinical study results.",{"count":165,"type":21},90,[54],"there are numerous studies, most of which are predominantly associative in nature, investigating the association between the gut microbiota and various pathologies. However, to establish a causal relationship between microbiome composition and chronic heart failure (HF), clinical studies are needed, particularly using probiotics that can modify the composition and function of the gut microbiota. Examining their effects on HF can help understand which specific changes are associated with improvement or slowing the progression of the disease. The gut microbiome plays an important role in regulating the immune system and inflammatory processes. Investigating the impact of probiotics on these mechanisms may reveal their potential anti-inflammatory and immunomodulatory properties, which can be beneficial for controlling the inflammation characteristic of HF. Additionally, studying the interaction of probiotics with other medications, such as antihypertensive and diuretic agents, can be crucial for optimizing pharmacotherapy in HF patients. Confirming the role of the gut microbiota in the pathogenesis of HF and further developing probiotic therapy may lead to improved prognosis and treatment outcomes for HF patients. Overall, conducting a clinical study using probiotics in HF has the potential to expand our knowledge of the role of the gut microbiota in this disease and lay the groundwork for the development of new treatment strategies.",[169],"Heart Failure","RECRUITING","2024-08-23",{"date":173,"type":33},"2024-08-27",{"date":151,"type":21},{"date":176,"type":21},"2025-10-31",{"name":39,"class":40},""]